Therapeutic Areas
Where wefocus
We work where human biology gives a clear signal and patients have too few options: five therapeutic areas, chosen for evidence and unmet need.
- Strong genetic evidenceAreas with rich human-genetics and omics data for causal target discovery.
- High unmet needDiseases where current treatments leave many patients behind.
Focus areas
Five areas, eight programmes
OncologyPlaceholder
Selective small molecules and antibodies against tumour-driving signalling and tumour-restricted antigens.
3 programmes
ImmunologyPlaceholder
Rebalancing pathological immune signalling in chronic inflammatory disease.
1 programme
CardiometabolicPlaceholder
Liver-targeted gene silencing guided by protective human genetic variants.
1 programme
NeurologyPlaceholder
Brain-penetrant molecules against neuro-inflammatory drivers of neurodegeneration.
1 programme
Rare diseasePlaceholder
mRNA and gene-therapy concepts for monogenic disorders with no approved therapy.
2 programmes
Pipeline
Programmes in progress
| Programme | Modality | Area | DiscoveryLead opt.PreclinicalClinical |
|---|---|---|---|
| AR-101 | Small molecule | Oncology | Preclinical |
| AR-204 | Antibody | Immunology | Preclinical |
| AR-117 | Small molecule | Oncology | Lead optimisation |
| AR-310 | siRNA | Cardiometabolic | Lead optimisation |
| AR-122 | Small molecule | Neurology | Discovery |
| AR-215 | Antibody | Oncology | Discovery |
| AR-402 | mRNA | Rare disease | Discovery |
| AR-501 | Gene therapy | Rare disease | Discovery |